2026

Alfort Stick, oral solution, Delta Medical Promotions AG, Switzerland

Summary of the risk management plan for a medicinal product for short-term symptomatic treatment of acute pain of mild and moderate intensity (musculoskeletal pain, dysmenorrhoea, toothache) in adults; contains an overview of the epidemiology of these conditions. compiled automatically

ICSJEVA®, solution for injection, Amgen Europe B.V., the Netherlands

Summary of the risk management plan for a medicinal product based on denosumab, intended for the prevention of bone complications in oncology patients. The document describes the important risks of the medicinal product, measures for their minimisation and planned studies to obtain additional information. compiled automatically

Aranesp, solution for injection, Amgen Europe B.V., the Netherlands

This is a summary of the risk management plan for a medicinal product containing darbepoetin alfa. The document describes the important risks of use, measures for their minimisation and planned studies to obtain additional safety information. compiled automatically

Lornado, lyophilisate for solution for injection, WORLD MEDICINE LLC, Ukraine

Summary of the risk management plan for a medicinal product based on lornoxicam for parenteral use, intended for short-term symptomatic treatment of acute pain of mild and moderate severity in adults. The document describes important risks, measures for their minimisation and further monitoring. compiled automatically

HELPEX® LAR, throat rinse, solution, Mowi Health GmbH

Summary of the risk management plan for a medicinal product for gargling based on chlorhexidine and benzydamine, intended for the treatment of inflammatory and infectious diseases of the oral cavity and pharynx. The document describes important risks, measures for their minimisation and routine pharmacovigilance activities. compiled automatically

Eurofast Combo, soft capsules, Euro Lifecare Private Limited, India

Summary of the risk management plan for a medicinal product based on ibuprofen and paracetamol intended for the symptomatic treatment of pain of various origins and fever. The document describes important risks, measures for their minimisation and routine pharmacovigilance activities. compiled automatically

Quetiapine-Darnytsia, film-coated tablets, PJSC “Pharmaceutical Firm “Darnytsia”

Summary of the risk management plan for a medicinal product based on quetiapine in the form of film-coated tablets intended for the treatment of schizophrenia and bipolar disorders. The document describes important risks, measures for their minimisation and routine pharmacovigilance activities. compiled automatically

TIARA A®, film-coated tablets, PJSC "Pharmaceutical Firm "Darnytsia"

Summary of the risk management plan for a medicinal product for the treatment of essential hypertension in adults, containing amlodipine besylate and valsartan. The document describes important risks, measures for their minimisation and routine pharmacovigilance activities. compiled automatically

Tonzihelp, oromucosal spray, Ananta Medicare Ltd., Great Britain

Summary of the risk management plan for a medicinal product based on benzydamine in the form of an oromucosal spray indicated for the symptomatic treatment of inflammations of the oropharynx, pain in gingivitis, stomatitis, pharyngitis and in dentistry. The document describes important risks, measures for their minimization and routine pharmacovigilance activities. compiled automatically

Донекс, таблетки, ТОВ «Асіно Україна», Україна